Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage
biopharmaceutical company developing a pipeline of novel drug
candidates against validated molecular targets in indications of
high unmet medical need, today announced it will participate in a
Symposium presentation, entitled Diabetic Cardiomyopathy (DbCM): a
severe complication of diabetes, at the 59th European Association
for the Study of Diabetes (EASD) Annual Meeting to take place
October 2-6, 2023 in Hamburg, Germany and online.
“Patients with diabetes are at a high risk of
developing overt heart failure even when optimal glucose control is
achieved,” said Riccardo Perfetti, MD, PhD, Chief Medical Officer
at Applied Therapeutics. “Diabetic Cardiomyopathy (DbCM) is a
severe disease affecting approximately 20% of patients with
diabetes. The Phase 3 ARISE-HF study is investigating the potential
benefit of AT-001 in treating DbCM, and we look forward to the data
readout later this year.”
Symposium presentation agenda
Diabetic Cardiomyopathy (DbCM): A Severe Complication of
DiabetesThursday, October 5
5:30PM - 5:35PMIntroductionStefano Del Prato,
MD, Chief of the Section of Diabetes, University Hospital of Pisa,
Italy
5:35PM - 5:55PMDiabetic Cardiomyopathy: Molecular
MechanismGary Lopaschuk, PhD, Professor, Department of
Pediatrics, University of Alberta, Edmonton, CanadaScientific
Director, Mazankowski Alberta Heart Institute
5:55PM - 6:15PMDiagnosis of Diabetic Cardiomyopathy
Based on Circulating Markers of Disease: Lessons from the Baseline
Analysis of the ARISE-HF StudyRiccardo Perfetti, MD, PhD,
Chief Medical Officer, Applied Therapeutics, New York City, USA
6:15PM - 6:30PMQuestions and Answers
About AT-001AT-001 (also called caficrestat) is
an investigational oral, novel, potent Aldose Reductase inhibitor
in Phase 3 clinical development for the treatment of Diabetic
Cardiomyopathy. The global ARISE-HF study is currently ongoing, and
is designed to evaluate the ability of AT-001 to improve or prevent
worsening of disease, as measured by changes in cardiac functional
capacity, in approximately 675 patients with DbCM at high risk of
progression to overt heart failure. AT-001 has been previously
studied in a Phase 1/2 study in approximately 120 patients with
type 2 diabetes, a subset of which had DbCM.
About Applied Therapeutics
Applied Therapeutics is a clinical-stage biopharmaceutical
company developing a pipeline of novel drug candidates against
validated molecular targets in indications of high unmet medical
need. The Company’s lead drug candidate, govorestat, is a novel
central nervous system penetrant Aldose Reductase Inhibitor (ARI)
for the treatment of CNS rare metabolic diseases, including
Galactosemia, SORD Deficiency, and PMM2-CDG. The Company is also
developing AT-001, a novel potent ARI, for the treatment of
Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart.
The preclinical pipeline also includes AT-003, an ARI designed to
cross through the back of the eye when dosed orally, for the
treatment of Diabetic Retinopathy.
To learn more, please visit www.appliedtherapeutics.com and
follow the company on Twitter @Applied_Tx.
Forward-Looking Statements
This press release contains “forward-looking statements” that
involve substantial risks and uncertainties for purposes of the
safe harbor provided by the Private Securities Litigation Reform
Act of 1995. Any statements, other than statements of historical
fact, included in this press release regarding strategy, future
operations, prospects, plans and objectives of management,
including words such as “may,” “will,” “expect,” “anticipate,”
“plan,” “intend,” and similar expressions (as well as other words
or expressions referencing future events, conditions or
circumstances) are forward-looking statements. Forward-looking
statements in this release, including those about the timing of our
topline data, involve substantial risks and uncertainties that
could cause actual results to differ materially from those
expressed or implied by the forward-looking statements, and we,
therefore cannot assure you that our plans, intentions,
expectations, or strategies will be attained or achieved.
Such risks and uncertainties include, without limitation,
factors that may cause actual results to differ from those
expressed or implied in the forward-looking statements in this
press release are discussed in our filings with the U.S. Securities
and Exchange Commission, including the “Risk Factors” contained
therein. Except as otherwise required by law, we disclaim any
intention or obligation to update or revise any forward-looking
statements, which speak only as of the date they were made, whether
as a result of new information, future events or circumstances or
otherwise.
Contacts
Investors: Maeve Conneighton(212)
600-1902appliedtherapeutics@argotpartners.com
Media: media@appliedtherapeutics.com
Applied Therapeutics, Inc.
Applied Therapeutics (NASDAQ:APLT)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Applied Therapeutics (NASDAQ:APLT)
Gráfica de Acción Histórica
De May 2023 a May 2024